Supriya Lifescience Ratios

Supriya Lifescience Ltd Ratios

The Supriya Lifescience Ltd Ratios page provides a complete fundamental analysis of Supriya Lifescience Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Supriya Lifescience Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Supriya Lifescience Ltd (NSE: SUPRIYA, BSE: 543434) is currently trading at ₹655, with a market capitalization of ₹52.58B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Supriya Lifescience Ltd remains a key stock for fundamental analysis using Supriya Lifescience Ltd Ratios.

Supriya Lifescience Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Supriya Lifescience Ltd P/E ratio currently stands at 31.41, making it one of the most tracked metrics in Supriya Lifescience Ltd Ratios.

Historically, the Supriya Lifescience Ltd P/E ratio has shown strong fluctuations:

• 2024: 31.41
• 2023: 22.42
• 2022: 17.08
• 2021: 26.13
• 2020: 0

The rising Supriya Lifescience Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Supriya Lifescience Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.92.

Historical P/B trend:

• 2024: 5.92
• 2023: 3.27
• 2022: 2.19
• 2021: 6.44

Supriya Lifescience Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Supriya Lifescience Ltd P/S ratio currently stands at 8.69, an important part of Supriya Lifescience Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 8.69
• 2023: 4.79
• 2022: 3.41
• 2021: 7.63

The rising Supriya Lifescience Ltd P/S ratio indicates improved revenue valuation by investors.

Supriya Lifescience Ltd Price to Cash Flow Ratio (P/CF)

The Supriya Lifescience Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 34.21.

Historical Supriya Lifescience Ltd Price to Cash Flow Ratio:

• 2024: 34.21
• 2023: 21.65
• 2022: 21.14
• 2021: 75.98
• 2020: 0

The rising Supriya Lifescience Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Supriya Lifescience Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Supriya Lifescience Ltd EV currently stands at ₹58.3B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 58.3B
• 2023: 26.01B
• 2022: 14B
• 2021: 37.67B

Supriya Lifescience Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Supriya Lifescience Ltd EV/EBITDA ratio is currently 22.85, a key metric in Supriya Lifescience Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 22.85
• 2023: 15.35
• 2022: 10.99
• 2021: 17.89

Higher Supriya Lifescience Ltd EV/EBITDA suggests premium valuation.

Supriya Lifescience Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Supriya Lifescience Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.01
• 2023: 0.01
• 2022: 0.03
• 2021: 0.04

Supriya Lifescience Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Supriya Lifescience Ltd ROE currently stands at 20.74%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 20.74
• 2023: 15.73
• 2022: 13.66
• 2021: 34.34

Supriya Lifescience Ltd demonstrates strong profitability and efficient capital utilization.

Supriya Lifescience Ltd Ratios Analysis Summary

The Supriya Lifescience Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Supriya Lifescience Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Supriya Lifescience Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.